Date:10/21/2009

aid per share $.49 $.47 4% $1.47 $1.41 4% Weighted- average shares outstanding (thousands) - basic 1,097,673 1,093,977 1,097,352 1,093,872 Weighted- average shares outstanding (thousands) - diluted 1,097,700 1,094,024 1,097,382 1,093,927 NM - not meaningful (a) The third quarter and year-to-date 2009 financial statements have been adjusted to eliminate an asset impairment and restructuring charge of $424.8 million (pretax), or $0.26 (after-tax). This charge is primarily related to the sale of the company's Tippecanoe manufacturing site and the severance costs associated with the sale. In addition, the third quarter and year-to-date 2009 financial statements have been adjusted to eliminate a special charge of $125.0 million (pretax), or $0.07 per share (after-tax), related to the currently probable and estimable exposures in connection with several states' litigation claims involving Zyprexa. (b) The 2009 year-to-date financial statements have also been adjusted to eliminate an additional special pretax charge of $105.0 million, or $0.06 per share (after-tax), representing the currently probable and estimable exposures in connection with several states' litigation claims involving Zyprexa. (c ) The third-quarter and year-to-date 2008 financial statements have been adjusted to reflect the acquisition of ImClone as if it was completed by Lilly effective January 1, 2008. The 2008 third-quarter and year-to-date amounts have also been adjusted to eliminate a charge of $28.0 million (no tax benefit), or $0.03 per share, for acquired in-process research and development related to the SGX acquisition; a charge of $182.4 million (pre-tax), or $0.11 per share (
'/>"/>

SOURCE Eli Lilly and Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Related medicine technology :

1. Lilly Declares Fourth-Quarter Dividend
2. Lilly to Sell Tippecanoe Manufacturing Site to Evonik Industries
3. Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
4. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
5. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
6. Study Showed Lillys GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
7. Lilly Advances Second Alzheimers Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
8. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
9. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
10. FDA Issues a Complete Response Letter for Lillys Olanzapine LAI for Treatment of Schizophrenia in Adults
11. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain